Anagliptin Improves LDL Partly Via ApoB-100 Suppression
The results demonstrated a tendency for a decrease in LDL-C level at 24 weeks in the ANA group, and improvement was mediated through the suppression of apoB-100 synthesis.
(HealthDay News) — In patients with type 2 diabetes being treated with a dipeptidyl peptidase-4 inhibitor (DPP4-I), use of anagliptin (ANA) may improve low-density lipoprotein cholesterol (LDL-C) levels, with the effect mediated, at least partly, via suppression of apoB-100 synthesis, according to a study published online in the Journal of Diabetes Investigation.
Akira Kurozumi, MD, from the University of Occupational and Environmental Health in Kitakyushu. Japan, and colleagues studied 87 patients with type 2 diabetes who had been treated with DPP4-I for 8 weeks or longer and had LDL-C of 120 mg/dl or higher. Participants were switched to either 200 mg/day ANA or 25 mg/day alogliptin (ALO) for 24 weeks.
The researchers found that there was no significant difference in percent change in LDL-C level between the two groups at 24 weeks. Treatment with ANA for 12 weeks significantly decreased LDL-C levels. Treatment with ANA for 24 weeks significantly improved apolipoprotein B-100 (apoB-100) levels. The percent change in LDL-C levels at 24 weeks correlated significantly with the percent change in apoB-100 levels in the ANA group.
"The results demonstrated a tendency for a decrease in LDL-C level at 24 weeks in the ANA group, and that such improvement was mediated, at least in part, through the suppression of apoB-100 synthesis," the authors write.
One author disclosed financial ties to the pharmaceutical industry.
- Kurozumi A, Okada Y, Arao T, et al. Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus. J Diabetes Investig. 2017 Aug 29. doi: 10.1111/jdi.12739